Form 4 holding
Director
DYNAVAX TECHNOLOGIES CORP
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 10 Feb 2026
- Price
- $15.72
- Ownership
- Direct
Daniel L. Kisner
Insider Reports History
- Reporting-owner location
- Carlsbad, CA
- Latest reporting-owner signature
-
/s/ Daniel L. Kisner, by /s/ Trevor Dutcher, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Daniel L. Kisner
Form 4 holding
Director
Histogen Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 6,835
- Estimated value
- Report date
- 20 Jun 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Oncternal Therapeutics, Inc.
- Security class
- Stock Options
- Shares / value
- 2,200
- Estimated value
- Report date
- 20 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
DYNAVAX TECHNOLOGIES CORP
- Security class
- Common Stock - Restricted Stock Units
- Shares / value
- 0
- Estimated value
- Report date
- 10 Feb 2026
- Price
- Ownership
- Direct
Form 4 holding
Director
DYNAVAX TECHNOLOGIES CORP
- Security class
- Stock Option (Right o Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 10 Feb 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
DYNAVAX TECHNOLOGIES CORP
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 10 Feb 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Zynerba Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Oct 2023
- Price
- $1.33
- Ownership
- Direct
Form 4 holding
Director
Zynerba Pharmaceuticals, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 10 Oct 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Daniel L. Kisner
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 10 Feb 2026
- Transactions
- 9
- Transaction value
- $0
- Accepted by SEC
- 10 Feb 2026, 16:15
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 11 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2025, 17:53
- Role
- Director
- Next action
- Open filing details
4
Oncternal Therapeutics, Inc.
- Report period
- 20 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 24 Jun 2024, 16:05
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 23 May 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 28 May 2024, 20:28
- Role
- Director
- Next action
- Open filing details
4
Zynerba Pharmaceuticals, Inc.
- Report period
- 10 Oct 2023
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 11 Oct 2023, 09:52
- Role
- Director
- Next action
- Open filing details
4
Oncternal Therapeutics, Inc.
- Report period
- 28 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 30 Jun 2023, 16:00
- Role
- Director
- Next action
- Open filing details
4
Histogen Inc.
- Report period
- 20 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2023, 16:09
- Role
- Director
- Next action
- Open filing details
4
Zynerba Pharmaceuticals, Inc.
- Report period
- 13 Jun 2023
- Transactions
- 3
- Transaction value
- -$40.03
- Accepted by SEC
- 15 Jun 2023, 16:29
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 26 May 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 31 May 2023, 17:25
- Role
- Director
- Next action
- Open filing details
4
Oncternal Therapeutics, Inc.
- Report period
- 16 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Jun 2022, 18:00
- Role
- Director
- Next action
- Open filing details
4
Zynerba Pharmaceuticals, Inc.
- Report period
- 14 Jun 2022
- Transactions
- 3
- Transaction value
- -$40.4
- Accepted by SEC
- 16 Jun 2022, 21:53
- Role
- Director
- Next action
- Open filing details
4
Histogen Inc.
- Report period
- 01 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Jun 2022, 16:38
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 26 May 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 27 May 2022, 17:00
- Role
- Director
- Next action
- Open filing details
4
Histogen Inc.
- Report period
- 02 Sep 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Sep 2021, 16:08
- Role
- Director
- Next action
- Open filing details
4
Zynerba Pharmaceuticals, Inc.
- Report period
- 03 Aug 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Aug 2021, 17:25
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 28 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2021, 19:06
- Role
- Director
- Next action
- Open filing details
4
Oncternal Therapeutics, Inc.
- Report period
- 25 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 27 May 2021, 18:09
- Role
- Director
- Next action
- Open filing details